Key result
The hERG IC50:Cmax ratio significantly correlated with TdP risk (correlation 0.312; 95% CI 0.205-0.476; p<0.0001), supporting its use for clinical decision making in drug selection.
Why the study?
Does the hERG IC50:Cmax ratio predict the risk of drug-induced Torsades de Pointes?
Population
Cases of drug-induced Torsades de Pointes from antihistamine, fluoroquinolone, and antipsychotic classes…
Design
Meta-analysis
Authors
Loading...
Supports using hERG IC50:Cmax ratio to guide safer drug selection and lower TdP risk; confirms its predictive value in meta-analysis.
Meta-Analysis
Does the hERG IC50:Cmax ratio predict the risk of drug-induced Torsades de Pointes?
Effect estimate: Correlation 0.312 (95% CI 0.205-0.476)
p-value: p=<0.0001
The hERG IC50:Cmax ratio correlates with TdP incidence and can be used for clinical decision-making when selecting drugs to minimize TdP risk.
Lehmann et al. (2018) conducted a meta-analysis in Drug-induced Torsades de Pointes (TdP). hERG IC50:Cmax ratio was evaluated on Correlation of hERG IC50:Cmax ratio with TdP incidence (Correlation 0.312, 95% CI 0.205-0.476, p=<0.0001). The hERG IC50:Cmax ratio significantly correlated with TdP risk (correlation 0.312; 95% CI 0.205-0.476; p<0.0001), supporting its use for clinical decision making in drug selection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: